medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number 01

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (01)

Demographic, biochemical and symptomatic description according to STRAW + 10 reproductive stages in Mexican women in peri and postmenopause

Ortiz-Luna GF, Arellano-Eguiluz A, Sánchez-Ceballos A, Salazar-Jiménez C, Escobar-Del Barco LG, Zavala-García A

Language: Spanish
References: 37
Page: 29-40
PDF size: 267.40 Kb.


ABSTRACT

Objective: Categorize the demographic, biochemical and symptomatic profile of the Mexican population served at the Instituto Nacional de Perinatología to describe their behavior in the stages of reproductive aging.
Materials and Methods: The following is an observational, descriptive, cross sectional study women from the Peri- and Postmenopause clinic at the National Institute of Perinatology in Mexico that enrolled 741 women over 41 years of age with a diagnosis of menopause according to the STRAW+10 criteria and classified in three categories: Category 1 (-2 to -1), Category 2 (+1A to +1C), and Category 3 (+2). The statistical analysis was performed by measure of central tendency, χ2 and ANOVA for the inferential analysis.
Results: In our population of 741 women, the average age at menopause was 50.08 years, while the population’s age average was 57.11 years. Average body mass index was 27.92 kg/m2, with 56.2% of the population within obesity range. The most prevalent comorbidity was arterial hypertension and the most frequent symptom was hot flushes. Hot flushes were most prevalent during the transition to menopause.
Conclusions: The STRAW+10 is an objective way to clinically classify patients in transition to menopause. There is an important need for more population-based studies in women to describe the reproductive ageing behavior in Mexico.


REFERENCES

  1. Shifren JL, Gass ML. The North American Menopause Society Recommendations for Clinical Care of Midlife Women. Menopause. 2014; 21 (10): 1038-62. doi: 10.1097/ GME.0000000000000319

  2. Hall JE. Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 2015;44(3):485-96. doi: 10.1016/j. ecl.2015.05.010.

  3. Harlow SD, et al. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19 (4): 387-95. doi: 10.1210/jc.2011-3362.

  4. Polotsky HN, Polotsky AJ. Metabolic implications of menopause. Semin Reprod Med. 2010; 28 (5): 426-34. doiI: 10.1055/s-0030-1262902.

  5. Roberts H, Hickey M. Managing the menopause: An update. Maturitas 2016; 86: 53-8. doi: 10.1016/j. maturitas. 2016.01.007.

  6. Santoro N, et al. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015; 44 (3): 497-515. doi: 10.1016/j.ecl.2015.05.001.

  7. Potter B, et al. Menopause. Prim Care. 2018; 45 (4): 625-41. doi: 10.1016/j.pop.2018.08.001.

  8. El Khoudary SR, et al. Cardiovascular fat, menopause, and sex hormones in women: The SWAN Cardiovascular Fat Ancillary Study. J Clin Endocrinol Metab. 2015; 100 (9): 3304-12. doi: 10.1210/JC.2015-2110.

  9. Lovejoy JC, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008; 32 (6): 949-58. doi: 10.1038/ijo.2008.25.

  10. Burguer, HG. The stages of reproductive aging as proposed by workshops held in 2001 and 2010 (STRAW and STRAW+10): A commentary. Climateric 2013; 16: 5-7. doi: 10.3109/13697137.2013.798769.

  11. Freeman EW, et al. Association of anti-müllerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007; 87: 101-6.

  12. Gracia CR, et al. The relationship between obesity and race on inhibin B during the menopause transition. Menopause 2005; 12: 559-66.

  13. Huddleston HG, et al. Racial and ethnic disparities in reproductive endocrinology and infertility. Am J Obstet Gynecol 2010; 202: 413-19.

  14. Harlow, SD. Menstrual cycle changes as women approach the final menses: What matters? Obstet Gynecol Clin N Am. 2018; 45: 599-611. doi: 10.1016/j.ogc.2018.07.003.

  15. Gold EB, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006; 96: 1226-35. doi: 10.2105/AJPH.2005.066936.

  16. Szoeke C, et al. Cohort Profile: women´s healthy ageing project (WHAP)-a longitudinal prospective study of Australian women since 1990. Womens Midlife Health 2016; 2:5. doi: 10.1186/s40695-016-0018-y.

  17. Freeman E, Sammel, MD. Methods in longitudinal cohort study of late reproductive age women: The Penn Ovarian Aging Study (POAS). Women’s Midlife Health, 2016; 2:1. doi: 10.1186/s40695-016-0014-2.

  18. Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Women’s Health 2015; 11 (2): 169-82. doi: 10.2217/whe.14.82.

  19. Amore M, et al. Psychological status at the menopausal transition: an Italian epidemiological study. Maturitas. 2004; 48 (2): 115-24.

  20. Iñigo RCA, et al. Factores de riesgo cardiovascular en el climaterio. Ginecol Obstet Mex. 2009; 77 (12): 535-43.

  21. Muñoz-Enciso JM, Rosales-Aujang E, Arias-Ulloa R. Trastornos metabólicos de mujeres en el climaterio. Ginecol Obstet Mex. 2013; 81: 186-9.

  22. Miguel-Soca PE, et al. Factores de riesgo de enfermedad cardiovascular en mujeres con menopausia. Rev Fed Arg Cardiol. 2014; 43 (2): 90-6.

  23. Oramas HL, et al. Riesgo cardiovascular en mujeres de edad mediana en el Policlínico “Mártires del Corynthia”. Rev Cubana Obstet Ginecol. 2016; 42 (1).

  24. Pérez JA, et al. Epidemiology of risk factors and symptoms associated with menopause in Spanish women. Maturitas. 2009; 62 (1):30-6.

  25. Honour JW. Biochemistry of the menopause. Ann Clin Biochem. 2018; 55(1): 18-33. doi: 10.1177/0004563217739930.

  26. Kaya C, et al. The relation among steroid hormone levels, lipid profile and menopausal symptom severity. J Psichosom Obstet Gynaecol. 2017; 38 (4): 284-91. doi: 10.1080/0167482X.2017.1321633.

  27. Zsakai A, et al. The relationship between reproductive and biochemical ageing at the time of the menopausal transition. Exp Gerontol. 2017; 98: 162-68. doi: 10.1016/j. exger.2017.08.028.

  28. Tremollieres FA, et al. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999; 142: 415-23. PMID: 10030394.

  29. Graff-Iversen S, et al. Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil 2008; 15: 83-8. doi: 10.1097/ HJR.0b013e3282f0e357.

  30. Adeli, K, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. Clin Chem. 2015; 61:1049-62. doi: 10.1373/clinchem.2015.240515.

  31. Bojar I, et al. Cognitive functions, lipid profile, and Apolipoprotein E gene polymorphism in postmenopausal women. Ann Agric Environ Med. 2015; 22(2): 313-9. doi: 10.5604/12321966.1152086.

  32. Cui Y, et al. The pattern of lipids and lipoproteins during the menopausal transition in Chinese women, Climacteric 2016. doi: 10.3109/13697137.2015.1130694.

  33. Sun N, et al. Impact of menopause on quality of life in community-based women in China; 1 year follow-up. Archives of Psychiatric Nursing 2017. doi: 10.1016/j. apnu.2017.11.005.

  34. Avis N, et al. Vasomotor symptoms across the Menopause transition. Differences among women. Obstet Gynecol Clin N Am. 2018; (45): 629-40.

  35. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2014; 123: 202-16. doi: 10.1097/01. AOG.0000441353.20693.78.

  36. Gracia C, Freeman E. Onset of the Menopause transition. The earliest signs and symptoms. Obstet Gynecol Clin N Am. 2018 (45): 585-97.

  37. Takahahi T, Johnson K. Menopause. Med Clin N Am. 2015; 99: 521-34.




2020     |     www.medigraphic.com